Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Launched by DANA-FARBER CANCER INSTITUTE · Mar 26, 2025

Keywords

ClinConnect Summary

The Tools for Reducing Inequity in Acute Leukemia (TRIAL) study is testing a new web-based application designed to help people diagnosed with acute leukemia. This application provides important information and resources about leukemia and how to participate in clinical trials, which are research studies that help find better treatments. The goal of the trial is to see how effective this tool can be in supporting patients during their treatment journey.

To be eligible for this study, participants need to be 18 years or older, speak English, and be suspected of having acute leukemia. They must also be admitted to a specific hospital unit for treatment. Participants should be able to understand and sign a consent form, which means they agree to take part in the study. Those with serious cognitive issues that prevent them from participating, or those who have already taken part in earlier testing of the application, will not be included. If you join, you can expect to help test the application in person and provide feedback on its usefulness. This is an important step in ensuring that patients have the tools they need to navigate their diagnosis and treatment effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 or older
• • English speaking
• • Ability to understand and willingness to sign written informed consent
• • Clinical suspicion of acute leukemia
• • Admitted to DFCI-affiliated inpatient unit
• Exclusion Criteria:
• • Cognitive impairment rendering the individual unable to participate in beta testing
• • This will be assessed by focused chart review and consultation with the patients' inpatient care team.
• • The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners.
• • Inability to participate in in-person application testing.
• • Patients who participated in alpha-testing through protocol 23-404 (Appendix A)